ARIELLA MARTIN: Open Payments
NPI 1497278378 · ROLLA, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$370 in 20 payments from 12 companies in 2025. Trend: 2023 $438 · 2024 $497 · 2025 $370
Food & beverage: $370
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Novo Nordisk Inc | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $26 |
| Ascensia Diabetes Care Us Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Lundbeck LLC | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| Organon LLC | 1 | $16 |
Products named: REXULTI, CAPLYTA, Wegovy, VOQUEZNA, Dexcom G6 Transmitter, MOUNJARO, TRELEGY ELLIPTA, Ozempic.
Industry payments across MO — which companies pay providers there.
